Full Text View
Tabular View
No Study Results Posted
Related Studies
The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients
This study has been terminated.
( In January, 2013 Merck had decided to take steps to suspend the availability of TREDAPTIVE globally )
Study NCT01052311   Information provided by Sheba Medical Center

First Received on January 16, 2010.   Last Updated on April 21, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Coronary Artery Disease
Dyslipidemia
Additional conditions recognized in this trial
Coronary Disease
Dyslipidemias
Myocardial Ischemia
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Vascular Diseases
Interventions listed in this trial
Placebo
Tredaptive
Additional drug interventions recognized in this trial
Niacin
Niacinamide
Nicotinic Acids
More general drug interventions related to this trial
Antimetabolites
Cardiovascular Agents
Growth Substances
Hypolipidemic Agents
Lipid Regulating Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents
Vitamin B Complex
Vitamins
Sponsors listed in this trial
Sheba Medical Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services